A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

• Published in: BMC cancer 2016-07, Vol.16 (1), p.405-405, Article 405
• Main Authors: Udeh, Emeka I, Ofoha, Chimaobi G, Adewole, David A, Nnabugwu, Ikenna I
• Format: Article
• Language: English
• Subjects: Analysis; Cost control; Cost-Benefit Analysis - methods; Disease; Dosage and administration; Drug Combinations; Drug dosages; Drug therapy, Combination; Dutasteride; Dutasteride - administration & dosage; Dutasteride - economics; Dutasteride - therapeutic use; GDP; Gross Domestic Product; Health Care Costs - statistics & numerical data; Health insurance; Hospitalization - statistics & numerical data; Humans; Hyperplasia; Hypertrophy; Informal economy; Male; Markov Chains; Middle Aged; Nigeria; Patients; Prostate; Prostatic Hyperplasia - drug therapy; Prostatic Hyperplasia - economics; Quality-Adjusted Life Years; Socioeconomic Factors; Sulfonamides - administration & dosage; Sulfonamides - economics; Sulfonamides - therapeutic use; Tamsulosin hydrochloride; Treatment Outcome; Urinary retention; Urinary Retention - epidemiology
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-016-2431-x

The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy from the health service provider perspective design. An interactive Markov's model was used to generate incremental cost per QALY and incremental cost per life years gained. 2.9 million Men who were 50 years of age were fed into the model. The outcome measures included: costs of drug treatment, consultation, acute urinary retention (AUR), transurethral resection of prostate (TURP), hospitalisation post TURP, and quality adjusted life years (QALYs), incremental cost per life years gained, and incremental cost per QALY gained. Fixed-dose combination of dutasteride and tamsulosin (FDCT) produced an Incremental cost-effectiveness ratios of US$1481.92 per Quality adjusted for life-years saved. Universal FDCT provision for Nigeria has major economic implications. This study in the context of its limitations has demonstrated the cost effectiveness of FDCT for the long term treatment of patients with moderate to severe BPH from the perspective of a developing country. Currently, there are few studies available to give economic data evidence to policy makers in Nigeria which is applicable to developing countries with similar economies. As such, the findings in this study will be relevant to policy makers in these countries.